Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of mRNA-1647 CMV Vaccine in Healthy Females 16–40 Years
2023-508820-37-00Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 13
01
Overview
Phase 3, randomised, single-blind trial in cytomegalovirus disease (CMV) comparing mRNA-1647 with Placebo (2 arms). Primary endpoints: Primary CMV infection and Safety and reactogenicity. Started Feb 2024; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2023-508820-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508820-37-00.